Nuclear Medicine

Medical Oncology

Questions discussed in this category

How do you interpret isolated PSMA-hypermetabolic sites in a patient with prostate cancer with no pelvic or RP LN uptake?

How do you discern false-positive PSMA PET sites? Is it typical to find metastatic disease without prior pelvic or RP node involvement?

3 Answers available

Would you continue serial PSMA PET scans after 2 negative scans for patients with a persistently rising PSA post-RT?

PSA > 2, and PSA doubling time < 1yr. Patient is resistant to ADT and did not tolerate the primary treatment. Would alternative PET imaging be r...

1 Answer available

What criteria are you using for retreatment with Pluvicto (Lu-177) in those who maintain a good performance status and appropriate lab work?

1 Answer available

What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?

1 Answer available

For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?

FDG PET, Axumin PET, Bone scan? Or just proceed with salvage ADT/RT?

4 Answers available

How do you manage dry eye related to Pluvicto Lu-177?

2 Answers available

Would you consider 177Lu-Dotatate (Lutathera) in patients with midgut neuroendocrine carcinoma after treatment with a somatostatin analog but with Ki67 >20%?

This patient had a Ki67 of 27%. However, the inclusion criteria for the NETTER-1 Trial was Ki67<20%. Would Lutathera be an option if labs are withi...

2 Answers available

For persistent PSA elevation after prostatectomy, would you recommend salvage radiation if pathologically negative nodes, but regional and non-regional lymphadenopathy on PSMA PET?

Specifically, would you offer salvage radiation to a patient who underwent a prostatectomy with PLND and had a post-op PSA of 12 with pathology reveal...

2 Answers available

Can PRRT be used in a patient with a GI neuroendocrine tumor and estimated GFR of less than 30?

1 Answer available

Papers discussed in this category

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005-01

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

J. Nucl. Med.,

NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of Lu-DOTATATE Peptide Receptor Radionuclide Therapy.

Neuroendocrinology, 2017 Apr 13

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues.

The New England journal of medicine, 2017-07-27

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-10

Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.

JAMA Oncol, 2021 Feb 18

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Endocr Relat Cancer,

Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.

J Nucl Med, 2018 Aug 16

Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.

Eur J Nucl Med Mol Imaging, 2017 Sep 12

Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.

N Engl J Med, 2021 Jun 23

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Clin Cancer Res, 2021 Feb 23

Diagnostic Performance of F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study.

European urology, 2023 Jul 05

Diagnostic Performance and Safety of Positron Emission Tomography with F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).

The Journal of urology, 2023 Apr 26

Diagnostic Performance and Safety of F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).

Skeletal Radiol, 2019 May 24

Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.

Cancer Imaging, 2020 Mar 14

Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings.

European journal of nuclear medicine and molecular imaging, 2020 Aug 17

False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018 Jan 25

68Ga-PSMA-HBED-CC Uptake in Cervical, Celiac, and Sacral Ganglia as an Important Pitfall in Prostate Cancer PET Imaging.

European radiology, 2025 Mar 20

PSMA-avid rib lesions in prostate cancer patients: differentiating false positives from metastatic disease.

BJU international, 2020 Jul 28

Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging Ga-PSMA-11 positron emission tomography scans for men with prostate cancer: benign or malignant?

Hellenic journal of nuclear medicine, 2024 Apr 18

A pictorial view on false positive findings of Ga-PSMA-11 PET/CT and their prognostic value in patients with prostate carcinoma after radical prostatectomy and undetectable PSA values.

Related Topics in Nuclear Medicine